If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Universities blast UN report on drug patents

by Glenn Hess, special to C&EN
September 26, 2016 | A version of this story appeared in Volume 94, Issue 38

Major research universities are slamming a report by a United Nations (UN) advisory panel that claims intellectual property rights, particularly patents, are largely to blame for high drug prices and lack of accessibility in developing countries. “A strong patent system is what allows universities and related technology transfer organizations to transmit the knowledge and innovations they produce for the public good and broader societal benefits,” five higher education groups say in a joint statement. The organizations, which include the Association of American Universities and the Association of University Technology Managers, responded to a Sept. 14 report issued by advisers to the UN Secretary-General on improving access to medicines. Among its recommendations, the panel suggested that nations should pursue compulsory licenses, which allow governments to override patents and allow the manufacture of lower-cost generic versions of brand-name medicines. But the universities called the focus on patents misguided. “In fact, intellectual property rights make the existence of, and access to, these critical drugs and technologies more likely, not less,” they say.

More online

Find out what all four major U.S. presidential candidates think about science at


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.